C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.
C5a receptor
C5a receptor inhibitor
IgA nephropathy
avacopan
complement
proteinuria
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
16
09
2021
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a receptor inhibitor, has previously shown efficacy in anti-neutrophil cytoplasmic antibody-associated vasculitis. The aim of this study was to evaluate the safety and efficacy of avacopan in patients with IgAN with persistent proteinuria despite a maximally tolerated dose of renin-angiotensin-aldosterone system blockade. The efficacy evaluation was based on the change in proteinuria. This open-label pilot trial enrolled adult patients with biopsy-proven IgAN, urinary protein:creatinine ratio (UPCR) >1 g/g creatinine and an estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m A total of 10 of 15 screened patients entered the run-in period. Seven patients with a UPCR >1 g/g creatinine received avacopan. Six of seven patients had numerical improvement in the UPCR during the avacopan treatment period, three of whom had a numerical improvement of ∼50% at week 12. At week 24, five of seven patients still showed numerical improvement in the UPCR compared with baseline. The urinary monocyte chemoattractant protein-1:creatinine ratio decreased numerically 30% by week 8, possibly reflecting the anti-inflammatory activity of avacopan. Avacopan was well tolerated. There was one serious adverse event of unstable angina, which was deemed to be unrelated to avacopan. This short-term pilot study showed an improvement in the slope of the UPCR, with ∼50% improvement in three of seven patients with IgAN. Longer avacopan treatment duration may be indicated for maximal benefit.
Sections du résumé
Background
UNASSIGNED
Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a receptor inhibitor, has previously shown efficacy in anti-neutrophil cytoplasmic antibody-associated vasculitis. The aim of this study was to evaluate the safety and efficacy of avacopan in patients with IgAN with persistent proteinuria despite a maximally tolerated dose of renin-angiotensin-aldosterone system blockade. The efficacy evaluation was based on the change in proteinuria.
Methods
UNASSIGNED
This open-label pilot trial enrolled adult patients with biopsy-proven IgAN, urinary protein:creatinine ratio (UPCR) >1 g/g creatinine and an estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m
Results
UNASSIGNED
A total of 10 of 15 screened patients entered the run-in period. Seven patients with a UPCR >1 g/g creatinine received avacopan. Six of seven patients had numerical improvement in the UPCR during the avacopan treatment period, three of whom had a numerical improvement of ∼50% at week 12. At week 24, five of seven patients still showed numerical improvement in the UPCR compared with baseline. The urinary monocyte chemoattractant protein-1:creatinine ratio decreased numerically 30% by week 8, possibly reflecting the anti-inflammatory activity of avacopan. Avacopan was well tolerated. There was one serious adverse event of unstable angina, which was deemed to be unrelated to avacopan.
Conclusions
UNASSIGNED
This short-term pilot study showed an improvement in the slope of the UPCR, with ∼50% improvement in three of seven patients with IgAN. Longer avacopan treatment duration may be indicated for maximal benefit.
Identifiants
pubmed: 35498891
doi: 10.1093/ckj/sfab294
pii: sfab294
pmc: PMC9050557
doi:
Types de publication
Journal Article
Langues
eng
Pagination
922-928Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
J Am Soc Nephrol. 1997 Feb;8(2):199-207
pubmed: 9048338
Kidney Int. 2020 Oct;98(4):1044-1052
pubmed: 32450154
J Am Soc Nephrol. 2006 Jun;17(6):1724-34
pubmed: 16687629
Nephrol Dial Transplant. 2019 Apr 1;34(4):587-596
pubmed: 29635535
J Urol Nephrol (Paris). 1968 Sep;74(9):694-5
pubmed: 4180586
N Engl J Med. 2013 Jun 20;368(25):2402-14
pubmed: 23782179
JAMA. 2017 Aug 1;318(5):432-442
pubmed: 28763548
Kidney Int. 2021 Oct;100(4S):S1-S276
pubmed: 34556256
N Engl J Med. 2015 Dec 3;373(23):2225-36
pubmed: 26630142
Lancet. 1999 Mar 13;353(9156):883-7
pubmed: 10093981
J Am Soc Nephrol. 2011 Oct;22(10):1795-803
pubmed: 21949093
PLoS One. 2014 Mar 21;9(3):e91756
pubmed: 24658533
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481
pubmed: 30635299
J Clin Immunol. 2014 Feb;34(2):224-32
pubmed: 24327134
N Engl J Med. 2021 Feb 18;384(7):599-609
pubmed: 33596356
Kidney Int Rep. 2020 Jul 23;5(10):1690-1699
pubmed: 33102961
Kidney Int. 2004 Sep;66(3):920-3
pubmed: 15327382
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):258-264
pubmed: 29146701
BMC Nephrol. 2019 Apr 30;20(1):150
pubmed: 31039758
Kidney Int. 2016 Jan;89(1):167-75
pubmed: 26759049
J Am Soc Nephrol. 2015 Sep;26(9):2248-58
pubmed: 25677392
J Am Soc Nephrol. 2017 Sep;28(9):2756-2767
pubmed: 28400446
J Am Soc Nephrol. 2014 Feb;25(2):225-31
pubmed: 24179165
Nephrol Dial Transplant. 2020 Jun 1;35(6):1002-1009
pubmed: 30418652
J Am Soc Nephrol. 2021 Feb;32(2):436-447
pubmed: 33514642
Nephrol Dial Transplant. 2020 Feb 1;35(2):283-291
pubmed: 30380100
Kidney Blood Press Res. 2016;41(6):997-1007
pubmed: 27988512